N末端脑钠肽前体在心力衰竭诊断中的应用价值
|
摘要
目的观察N末端脑钠肽前体检测在心力衰竭诊断中的应用价值。方法 54例心力衰竭患者设为研究组,同期于本院接受体检的54例健康者设为对照组。两组研究对象均接受N末端脑钠肽前体检测、左心室舒张末期内径及左心室射血分数超声检测。对比两组研究对象及研究组不同心功能分级患者的N末端脑钠肽前体、左心室舒张末期内径及左心室射血分数检测结果。结果研究组N末端脑钠肽前体为(751.46±337.58)ng/L,高于对照组的(34.04±18.26)ng/L,研究组左心室舒张末期内径为(59.73±8.59)mm,大于对照组的(46.62±5.51)mm,研究组左心室射血分数为(41.56±6.45)%,低于对照组的(62.54±5.27)%,差异均具有统计学意义(P<0.05)。研究组患者随着心功能分级的加大, N末端脑钠肽前体及左心室舒张末期内径逐渐增加,左心室射血分数逐渐降低,不同心功能分级间两两对比,差异均具有统计学意义(P<0.05)。结论在心力衰竭诊断中应用N末端脑钠肽前体检测,可有效反映患者心力衰竭的进展,并可结合心功能检测对其左心室功能开展有效评估,临床应用价值较高。
Objective To observe the value of N-terminal pro-brain natriuretic peptide detection applied in the diagnosis of heart failure. Methods There were 54 patients with heart failure as research group, and concurrent 54 healthy persons who received physical examination in our hospital as control group. Both groups received N-terminal pro-brain natriuretic peptide detectoin, left ventricular end-diastolic diameter and left ventricular ejection fraction ultrasound detection. The N-terminal pro-brain natriuretic peptide, left ventricular end-diastolic inner diameter and left ventricular ejection fraction of patients with different grades cardiac function were compared between the two groups and in the research group. Results The research group had higher N-terminal pro-brain natriuretic peptide as(751.46±337.58) ng/L than(34.04±18.26)ng/L in the control group, larger left ventricular end-diastolic inner diameter as(59.73±8.59) mm than(46.62±5.51) mm in the control group, and lower left ventricular ejection fraction as(41.56±6.45)% than(62.54±5.27)% in the control group. Their difference was statistically significant(P<0.05). With the increase of cardiac function grade, N-terminal pro-brain natriuretic peptide and left ventricular end-diastolic diameter gradually increased and left ventricular ejection fraction gradually decreased in the research group. There were significant differences between two different cardiac function grades(P<0.05). Conclusion The application of N-terminal brain natriuretic peptide precursor test in the diagnosis of heart failure can effectively reflect the progress of heart failure, and can effectively evaluate the left ventricular function with cardiac function test. It has high clinical application value.
Objective To observe the value of N-terminal pro-brain natriuretic peptide detection applied in the diagnosis of heart failure. Methods There were 54 patients with heart failure as research group, and concurrent 54 healthy persons who received physical examination in our hospital as control group. Both groups received N-terminal pro-brain natriuretic peptide detectoin, left ventricular end-diastolic diameter and left ventricular ejection fraction ultrasound detection. The N-terminal pro-brain natriuretic peptide, left ventricular end-diastolic inner diameter and left ventricular ejection fraction of patients with different grades cardiac function were compared between the two groups and in the research group. Results The research group had higher N-terminal pro-brain natriuretic peptide as(751.46±337.58) ng/L than(34.04±18.26)ng/L in the control group, larger left ventricular end-diastolic inner diameter as(59.73±8.59) mm than(46.62±5.51) mm in the control group, and lower left ventricular ejection fraction as(41.56±6.45)% than(62.54±5.27)% in the control group. Their difference was statistically significant(P<0.05). With the increase of cardiac function grade, N-terminal pro-brain natriuretic peptide and left ventricular end-diastolic diameter gradually increased and left ventricular ejection fraction gradually decreased in the research group. There were significant differences between two different cardiac function grades(P<0.05). Conclusion The application of N-terminal brain natriuretic peptide precursor test in the diagnosis of heart failure can effectively reflect the progress of heart failure, and can effectively evaluate the left ventricular function with cardiac function test. It has high clinical application value.
引文
[1]王璐,李晓晓,高枫,等. N-末端脑钠肽前体在心力衰竭患者心功能分级中的应用.检验医学与临床, 2015(15):2151-2152.
[2]罗莫孺. N端脑钠肽前体联合血清同型半胱氨酸检测对心力衰竭诊断价值评价.广东微量元素科学, 2016, 23(1):61-63.
[3]李令娟,杨秀玲,戴妍妍. N端脑钠肽前体及半乳糖凝集素-3在慢性心力衰竭诊断和治疗中的应用价值.国际检验医学杂志, 2017, 38(12):1676-1678.
[4]李雪峰,刘云双,乔智力,等. N端脑钠肽前体在舒张性心力衰竭早期诊断中的应用价值.医学综述, 2016, 22(15):3033-3036.
[5]范龙. N末端脑钠肽前体和相关生化指标对老年慢性心力衰竭的诊断价值.医学综述, 2015, 21(6):1112-1114.
[6]彭文君,方胜先,郭盛,等. N末端脑钠肽前体评价慢性心力衰竭患者心脏康复治疗效果.临床和实验医学杂志, 2011,10(12):893-894.
[7]王子健,华宝桐,王启贤.脑钠肽及N末端脑钠肽前体指导心力衰竭用药的研究进展.医学综述, 2013, 19(9):1619-1621.
[8]杨海波. N末端脑钠肽前体对老年心力衰竭患者预后的评估价值.中国医师进修杂志, 2013, 36(18):39-41.
[9]宛新民. N末端脑钠肽前体在心力衰竭患者中的应用.中国医药科学, 2011, 1(11):93-94.
[2]罗莫孺. N端脑钠肽前体联合血清同型半胱氨酸检测对心力衰竭诊断价值评价.广东微量元素科学, 2016, 23(1):61-63.
[3]李令娟,杨秀玲,戴妍妍. N端脑钠肽前体及半乳糖凝集素-3在慢性心力衰竭诊断和治疗中的应用价值.国际检验医学杂志, 2017, 38(12):1676-1678.
[4]李雪峰,刘云双,乔智力,等. N端脑钠肽前体在舒张性心力衰竭早期诊断中的应用价值.医学综述, 2016, 22(15):3033-3036.
[5]范龙. N末端脑钠肽前体和相关生化指标对老年慢性心力衰竭的诊断价值.医学综述, 2015, 21(6):1112-1114.
[6]彭文君,方胜先,郭盛,等. N末端脑钠肽前体评价慢性心力衰竭患者心脏康复治疗效果.临床和实验医学杂志, 2011,10(12):893-894.
[7]王子健,华宝桐,王启贤.脑钠肽及N末端脑钠肽前体指导心力衰竭用药的研究进展.医学综述, 2013, 19(9):1619-1621.
[8]杨海波. N末端脑钠肽前体对老年心力衰竭患者预后的评估价值.中国医师进修杂志, 2013, 36(18):39-41.
[9]宛新民. N末端脑钠肽前体在心力衰竭患者中的应用.中国医药科学, 2011, 1(11):93-94.